Trading / Browse Companies / Metacrine Stock

Metacrine Stock

metacrine.comHealthcareFounded: 2014Funding to Date: $134.77MM

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases.

Buy or sell Metacrine stockLearn more about a potential Metacrine IPO
Register for Details

For more details on financing and valuation for Metacrine, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Metacrine.

Register Today

Team

Management Team

Trisha Millican
Chief Financial Officer
Karl Cremer
Vice President, Clinical Operations
Michael Downes
Co-Founder
Kathie Huynh
Executive
Hubert Chen MD
Chief Medical Officer
Richard Heyman Ph.D
Co-Founder & Chairman
Nicholas Smith Ph.D
Senior Vice President, Chemistry
Eric Bischoff
Vice President, Development and Business Operations
Ken Song MD
President, Chief Executive Officer & Board Director

Board Members

Amir Nashat Ph.D
Polaris Partners
Richard Heyman Ph.D
Carol Gallagher
New Enterprise Associates
Kristina Burow
ARCH Venture Partners
Ronald Evans Ph.D
Andrew Guggenhime
Ken Song MD
Robert Adelman MD
venBio

Other companies like Metacrine in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.6B
NowRx
Sector
Healthcare
Last Round Est. Valuation
$334.19MM
Nutrafol
Sector
Healthcare
Last Round Est. Valuation
$150MM
Biosplice Therapeutics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Levels
Sector
Healthcare
Last Round Est. Valuation
$296.3MM
Cerebral
Sector
Healthcare
Last Round Est. Valuation
$4.8B

News

Globe Newswire 09/16/2020
Metacrine Announces Pricing of Initial Public Offering
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and...
Market Screener 09/18/2019
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
FinSMEs 06/08/2018
Metacrine Completes $65M Series C Financing |FinSMEs
Metacrine, Inc., a San Diego, CA-based innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, completed a $65m Series C financing

Trending Companies

Frequently Asked Questions